Advertisement

Journal of Neurology

, Volume 253, Issue 10, pp 1337–1341 | Cite as

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain

A double-blind placebo-controlled cross-over trial
  • Jörg Wissel
  • Tanja Haydn
  • Jörg Müller
  • Christian Brenneis
  • Thomas Berger
  • Werner Poewe
  • Ludwig D. Schelosky
ORIGINAL COMMUNICATION

Abstract

About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Δ9-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.

11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out).

Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.

Keywords

Nabilone synthetic cannabinoid spasticity central pain 

References

  1. 1.
    Shakespeare DT, Boggild M, Young C (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst RevCD001332Google Scholar
  2. 2.
    Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7:iii, ix–iii, 111Google Scholar
  3. 3.
    Iversen L (2003) Cannabis and the brain. Brain 126:1252–1270PubMedCrossRefGoogle Scholar
  4. 4.
    Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di MV (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300–302PubMedGoogle Scholar
  5. 5.
    Diana G, Malloni M, Pieri M (2003) Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission. Pharmacol Biochem Behav 75:585–591PubMedCrossRefGoogle Scholar
  6. 6.
    Rubin A, Lemberger L, Warrick P, Crabtree RE, Sullivan H, Rowe H, Obermeyer BD (1977) Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 22:85–91PubMedGoogle Scholar
  7. 7.
    Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48:657–663PubMedGoogle Scholar
  8. 8.
    Ward A, Holmes B (1985) Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 30:127–144PubMedGoogle Scholar
  9. 9.
    Kurzthaler I, Bodner T, Kemmler G, Entner T, Wissel J, Berger T, Fleischhacker WW (2005) The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 20:291–293PubMedCrossRefGoogle Scholar
  10. 10.
    Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44–49PubMedCrossRefGoogle Scholar
  11. 11.
    Maurer M, Henn V, Dittrich A, Hofmann A (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1–4PubMedCrossRefGoogle Scholar
  12. 12.
    Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579PubMedCrossRefGoogle Scholar
  13. 13.
    Hamann W, di Vadi PP (1999) Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 353:560PubMedCrossRefGoogle Scholar
  14. 14.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526PubMedCrossRefGoogle Scholar
  15. 15.
    Petro DJ, Ellenberger C Jr. (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413S–416SPubMedGoogle Scholar
  16. 16.
    Meinck HM, Schonle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120–122PubMedCrossRefGoogle Scholar
  17. 17.
    Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446–452PubMedGoogle Scholar
  18. 18.
    Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39–50PubMedGoogle Scholar
  19. 19.
    Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF (1994) Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324–328PubMedCrossRefGoogle Scholar
  20. 20.
    Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995) Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. Am J Ther 2:799–805PubMedCrossRefGoogle Scholar
  21. 21.
    Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404–1407PubMedGoogle Scholar
  22. 22.
    Killestein J, Uitdehaag BM, Polman CH (2004) Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 64:1–11PubMedCrossRefGoogle Scholar
  23. 23.
    Okie S (2005) Medical Marijuana and the Supreme Court. N Engl J Med 353:648–651PubMedCrossRefGoogle Scholar
  24. 24.
    Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165–174PubMedCrossRefGoogle Scholar
  25. 25.
    Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551PubMedCrossRefGoogle Scholar
  26. 26.
    Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2:291–298PubMedCrossRefGoogle Scholar
  27. 27.
    Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569–611PubMedCrossRefGoogle Scholar
  28. 28.
    Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13–16PubMedCrossRefGoogle Scholar
  30. 30.
    Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D (2004) Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8:173–177PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Jörg Wissel
    • 1
    • 3
  • Tanja Haydn
    • 1
  • Jörg Müller
    • 1
  • Christian Brenneis
    • 1
  • Thomas Berger
    • 1
  • Werner Poewe
    • 1
  • Ludwig D. Schelosky
    • 2
  1. 1.Dept. of NeurologyUniversity of InnsbruckInnsbruckAustria
  2. 2.Kantonsspital MünsterlingenMünsterlingenSwitzerland
  3. 3.Neurologische Rehabilitationsklinik, Kliniken Beelitz GmbHBeelitz-HeilstättenGermany

Personalised recommendations